Skip to content

KWF

Validation of Biomarkers 2027

€0.8M–€2M per proposal| Deadline: 20 October 2026 (118 days)|2–5 years

Pre-proposal deadline: 20 October 2026, 12:00 noon. Full proposal deadline: 23 February 2027, 12:00 noon.

Last verified:

Is this grant right for you? Check your personalised match score. 30s, no email. See my matches →

The KWF Validation of Biomarkers 2027 call funds clinical validation of known oncology biomarkers (technology-readiness level 5-6) for routine clinical use, with budgets of €0.8-2 million per project over 2-5 years. The call requires a multidisciplinary consortium of at least four parties, including a biostatistician and health-technology-assessment expert, plus mandatory patient involvement; public, private partnerships and co-funding are encouraged. This annual call emphasizes regulatory strategy, reimbursement pathways, and implementation planning alongside validation science.

Details

Funder KWF
Budget €0.8M–€2M per proposal
Deadline 20 October 2026
Duration 2–5 years
Consortium Required — minimum 4 participating parties (multidisciplinary consortium; private partners allowed)
Application 2-stage: pre-proposal (opens 25 Aug 2026, closes 20 Oct 2026) → full proposal (opens 15 Dec 2026, closes 23 Feb 2027) → interviews May 2027 → funding decision June 2027
TRL 5-6
Frequency Annual
Eligible countries NL

Eligibility & scope

Clinical validation of known oncology biomarkers (TRL5/6) for use in daily clinical practice. Requires multidisciplinary consortium of ≥4 parties including biostatistician and HTA expert; patient involvement mandatory. AI-component projects must engage the AI4HEALTH consortium. Public-private collaborations encouraged with co-funding. Dutch Cancer Society (KWF) call; host institutions likely Dutch-based.

Who Should Apply

  • Multidisciplinary teams of ≥4 parties: clinicians, researchers, biostatisticians, HTA specialists, and/or industry partners
  • Researchers based at Dutch academic hospitals, research institutes, or eligible private-sector organisations
  • Projects focused on clinical validation (TRL 5-6) of existing oncology biomarkers for diagnostic or prognostic use
  • Teams with demonstrable patient and patient-association involvement in consortium planning
  • Public, private collaborative consortia with co-funding are particularly competitive

Key Dates

  • Pre-proposal deadline: 20 October 2026, 12:00 noon; full proposal deadline: 23 February 2027, 12:00 noon
  • Two-stage process with shortlist interviews in May 2027 and funding decision in June 2027
  • Project duration: 2-5 years

Tips for Applicants

  • Consortium composition is gating: ensure your four-plus parties span clinical, statistical, regulatory, and HTA expertise; weak HTA or missing biostatistician will score poorly.
  • Lead with the regulatory and reimbursement pathway as a co-equal pillar to the clinical validation science; KWF explicitly scores implementation readiness.
  • AI-component projects must declare early engagement with the AI4HEALTH consortium; omission is a disqualifier, not a weakness to address in revision.

Frequently Asked Questions

What budget can I request for the Validation of Biomarkers 2027 call?

Projects receive €0.8-2 million per proposal. Consortium size, complexity, and the scope of the validation study determine where in that range your project sits.

Is a consortium required for Validation of Biomarkers 2027?

Yes, you must assemble a minimum of four participating parties, including a biostatistician and HTA expert; public, private partnerships and industry co-funding are encouraged.

Do AI-component projects have special requirements?

Yes, projects integrating artificial intelligence must engage the AI4HEALTH consortium early; this is a mandatory component, not optional.

How long does a project last under Validation of Biomarkers 2027?

Project duration is 2-5 years, depending on the scope and complexity of the biomarker validation.

What does the pre-proposal stage require?

The pre-proposal (due 20 October 2026) is a first competitive gate; shortlisted applicants receive feedback and are invited to submit a full proposal by 23 February 2027.

cancer-biologykwfbiomarker-validationclinical-translationconsortium-requiredtranslational-researchnetherlandshta

Related on Grantsby

Summary generated by AI based on published grant information. Always verify details on the funder's website.

More from KWF

Browse all open grants →

Browse Related

Could Validation of Biomarkers 2027 be right for you?

See your personalised match score for this grant and others in 30 seconds. No signup needed to preview.

See my matches free →